Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

John Ladas, ESCRS 2019 – AI approach to IOL power calculation

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 23rd 2019

John Ladas (Maryland Eye Consultants) talks about the challenges and recent studies on an artificial intelligence approach to IOL power calculations at ESCRS 2019.

Questions:
1. What are the limitations of current methods of intraocular lens (IOL) power calculation?
2. Could you tell us a little about the artificial intelligence (AI) approach to IOL power calculation?
3. What are the major challenges to using AI algorithms and how may they be overcome?
4. What clinical data supports the use of AI models?
5. What are the key take home messages of your presentation?

Support: No funding was received for the production of this video.
Disclosures: John Ladas is the founder of Advanced Euclidean Solutions.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup